• SENSEX
    NIFTY 50
Market

Tuesday's top brokerage calls: Info Edge, Aurobindo Pharma and more

Updated : 2020-09-22 08:51:36

Among brokerages, Nomura downgraded Info Edge to 'neutral' with a target at Rs 3,040 per share while Investec maintained a bullish view on Aurobindo Pharma and raised its target price. Here are the top brokerage calls for today:

 Nomura on Info Edge : The brokerage downgraded the stock to 'neutral' with a target at Rs 3,040 per share. It expects weakness in some of the company's core businesses like Nakuri and 99acres.
Nomura on Info Edge: The brokerage downgraded the stock to 'neutral' with a target at Rs 3,040 per share. It expects weakness in some of the company's core businesses like Nakuri and 99acres.
 Investec on Aurobindo Pharma:  The brokerage maintains a 'buy' call on the stock and has raised the target price to Rs 1,000 from Rs 755 earlier. With no leverage concerns, the stock is placed for a re-rating, it adds.
Investec on Aurobindo Pharma: The brokerage maintains a 'buy' call on the stock and has raised the target price to Rs 1,000 from Rs 755 earlier. With no leverage concerns, the stock is placed for a re-rating, it adds.
 CLSA on Economy : Improvement in economic indicators continues, January-March quarter of FY21 should see flat GDP YoY, CLSA says. It also expects most regulatory restrictions to ease by December 2020.
CLSA on Economy: Improvement in economic indicators continues, January-March quarter of FY21 should see flat GDP YoY, CLSA says. It also expects most regulatory restrictions to ease by December 2020.
 CLSA on Oil and Gas : Domestic gas price is set to be cut 26 percent on October 1 which is a big tailwind for city gas companies' margins, CLSA says. It added that trends suggest gains in transmission for GAIL and GSPL.
CLSA on Oil and Gas: Domestic gas price is set to be cut 26 percent on October 1 which is a big tailwind for city gas companies' margins, CLSA says. It added that trends suggest gains in transmission for GAIL and GSPL.
Live TV

recommended for you

Ask Our Experts CNBC TV18

Advertisement